Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

December 2, 2024

Patent Attorney Bill Braunlin Joins Barclay Damon's Expanding IP Practice Group

Barclay Damon announces Bill Braunlin, special counsel, has joined Barclay Damon’s Patents & Prosecution Practice Area, bolstering the firm’s Intellectual Property Practice Group with a wealth of experience in chemistry, biotechnology, and pharmaceuticals and substantial work with battery technologies. His primary office location is Boston.

Braunlin has nearly a decade of patent prosecution experience and a distinguished background as a physical chemist. His career spans academia, industry, and entrepreneurship, with significant accomplishments in nucleic acid biophysics, drug development, and advanced materials. Prior to joining Barclay Damon, Braunlin held patent attorney and patent agent roles at law firms in Boston, where he advised clients on patent drafting, prosecution, and portfolio development. Fluent in German and Swedish, Braunlin is adept at working with diverse teams and global stakeholders and collaborating with inventors to protect and commercialize their innovations.

"I’m thrilled to join Barclay Damon’s well-established intellectual property group and contribute to its reputation for delivering innovative solutions to clients," said Braunlin. "The firm’s collaborative culture and commitment to staying at the forefront of emerging industries provide an exciting opportunity to leverage my experience in patent law and science to help inventors and businesses protect and advance their groundbreaking work."

Braunlin’s academic and industrial achievements include leading research programs in molecular biophysics, co-founding Rational Affinity Devices to develop diagnostic technologies, and heading physical chemistry and biophysics groups at pharmaceutical and biotechnology companies. A prolific inventor and scholar, Braunlin is the primary author of nearly 40 peer-reviewed publications and has served as a reviewer for major grant agencies, including the NIH and NSF.

"Bill's technical knowledge and deep understanding of patent law make him an exceptional addition to our intellectual property team," said Denis Sullivan, Intellectual Property Practice Group leader at Barclay Damon. "His proven ability to navigate the complexities of patent prosecution in chemistry and biotechnology will enhance the services we provide to our clients."

Lizz Acee, managing director of Barclay Damon’s major market offices said, “Bill’s addition to our Boston office represents a significant milestone in our strategic growth in this vibrant legal and innovation hub. As our Boston office continues to expand, we remain committed to delivering top-tier intellectual property services to both established companies and emerging innovators.”

Barclay Damon attorneys team across offices and practices to provide customized, targeted solutions grounded in industry knowledge and a deep understanding of our clients' businesses. With nearly 300 attorneys, Barclay Damon is a leading regional law firm that operates from a strategic platform of offices in Albany, Boston, Buffalo, New Haven, New York City, Rochester, Syracuse, Washington DC, and Toronto. Our firm serves clients across the country and, for some practices, provides US legal services around the globe. For more information, visit our award-winning website at barclaydamon.com.

Featured Media

Alerts

Proposed Legislation Would Codify and Expand City and County Liability for Child Abuse Post-Weisbrod-Moore

Alerts

Federal Energy Regulatory Commission Issues Show Cause Orders Regarding Large Load Interconnection to the NY Independent System Operator, Other Regional Grid Operators

Alerts

New York Establishes First-in-the-Nation Statewide Moratorium on Data Center Permits

Alerts

Proposed Legislation Unlocks New Financing Options for NYS Affordable Housing Developers

Alerts

NYS Legislators Advance Patient Access to Pharmacy Act, Establishing New PBM Reimbursement Standards

Alerts

Prior Authorization Compliance: What NYS Pharmacies Need to Know to Avoid Medicaid, PBM, and Payor Enforcement Risks